Communiqués Genmab A/S Nasdaq

Actions

GMAB

US3723032062

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 12/06/2026			Varia. 5j.	Varia. 1 janv.
25,08 ^USD	-0,63%		-0,28%	-18,57%

11/06	Genmab : les données de sous-groupes pour le traitement du lymphome folliculaire confirment une efficacité " durable »	MT
11/06	Genmab A/S présente les données de sous-groupes de l'étude EPCORE FL-1 démontrant l'efficacité et la sécurité constantes de l'epcoritamab associé au rituximab et au lénalidomide (R2) chez les patients atteints d'un lymphome folliculaire en rechute ou réfractaire	CI

Communiqués

11/06	Grant of Restricted Stock Units and Warrants to Employees in Genmab	GL
11/06	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	BU
11/06	Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients	GL
29/05	Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons	GL
22/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology Annual Meeting and the European Hematology Association 2026 Congress	AQ
21/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	BU
21/05	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress	GL
13/05	Genmab A/S : Articles of association dated May 12, 2026 – English	PU
13/05	Genmab A/S : has published its Articles of Association	PU
12/05	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
11/05	Genmab - Major Shareholder Announcement	AQ
08/05	Major Shareholder Announcement	GL
07/05	Genmab A/S : Investor Presentation - May 2026	PU
07/05	Genmab A/S : First Quarter 2026 Financial Results Presentation	PU
07/05	Genmab A/S : Interim Report for the First Quarter of 2026	PU
07/05	Genmab Announces Financial Results for the First Quarter of 2026	GL
07/05	Genmab Announces Financial Results for the First Quarter of 2026	AQ
17/04	Genmab A/S : has published its Articles of Association	PU
17/04	Genmab A/S Share Capital Reduction	GL
14/04	Major Shareholder Announcement	GL
14/04	Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026	GL
13/04	Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer	BU
13/04	Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer	GL
07/04	Genmab A/S : AGM 2026 Presentation	PU
01/04	Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons	GL